Overview
- Bayer, which reported Tuesday a 9% rise in first‑quarter operating profit to about €4.4–€4.5 billion, said crop‑science sales grew roughly 7% with about €450 million from a one‑time Corteva license deal.
- In early June, roughly 67,000 remaining Roundup claimants decide whether to stay in a settlement that would pay up to €7.25 billion, a step that could shrink Bayer’s case load at once.
- By late July, the U.S. Supreme Court is expected to rule on whether Bayer had to add cancer warnings to Roundup labels, a decision that could weaken many lower‑court claims if the justices say no warning was required.
- After Congress stripped proposed liability shields from the Farm Bill, CEO Bill Anderson criticized lawmakers and warned Bayer could pull glyphosate from the U.S., citing a risk that supply would otherwise hinge on China.
- Legal uncertainty has already delayed the U.S. launch of Bayer’s new insecticide Plenexos, even as the company continues to absorb costs from the 2018 Monsanto deal that have topped €10 billion.